Corrado Advisors LLC Grows Stock Holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Corrado Advisors LLC boosted its holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 17.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,323 shares of the company’s stock after buying an additional 11,099 shares during the quarter. Corrado Advisors LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $731,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GNOM. James J. Burns & Company LLC increased its stake in Global X Genomics & Biotechnology ETF by 6.0% in the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after purchasing an additional 1,038 shares during the last quarter. Atria Investments Inc purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $122,000. Centaurus Financial Inc. lifted its position in shares of Global X Genomics & Biotechnology ETF by 7.0% during the 3rd quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock worth $169,000 after buying an additional 985 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 3rd quarter valued at $205,000. Finally, Flow Traders U.S. LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the 3rd quarter worth $936,000. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM opened at $9.43 on Thursday. Global X Genomics & Biotechnology ETF has a 1-year low of $9.29 and a 1-year high of $12.53. The stock has a market cap of $65.73 million, a PE ratio of -4.03 and a beta of 1.03. The firm has a fifty day moving average price of $9.90 and a 200 day moving average price of $10.52.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.